Enterprises do not usually fail at AI because one model gives a bad answer. They fail when no one can explain which model answered, what context it used, who approved it, how it changed, and whether it treated different groups fairly.

AI agents will not transform operations if they live only as IT experiments. They need a home inside the department whose work they are meant to improve. That was the central theme from an Ai4 session attended by Aaron McCormack of syswisdom.ai. The discussion pointed to a clear shift in how organizations should treat agents. Early AI projects often sat with technical teams because the tools were new, risky, and hard to integrate. That made sense at the start. But agents are

AI in medicine is no longer just a story about faster paperwork or smarter search. On Day 1, the sharper question was whether the same systems that can help design medicines, run experiments, and shorten research cycles can also be misused by people with harmful intent. That tension ran through the opening keynote, AI’s Race to Reinvent Medicine, featuring Gevorg Grigoryan, Co-Founder and CTO of Generate Biomedicines, Alice Park, Senior Health Correspondent at TIME, Alex Zhav